Advancing Medicine Is In Daniel MacArthur’s DNA

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.
Daniel MacArthur with Melbourne scientist and assistant professor Misty Jenkins. Both will be speaking at the Sohn Hearts & Minds conference in Sydney.

Glenda Korporaal

Advancing Medicine Is In Daniel MacArthur’s DNA

November 15, 2023
When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.
Read Transcript

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Based in Boston as co-director of the Medical and Population Genomics Program at the Broad Institute for Mendelian Genomics at MIT and Harvard, his work in the US had involved using new genomic technologies to help predict and diagnose diseases.

It included overseeing a team that built one of the largest genetic data bases ever assembled, collecting data from more than 140,000 people.

MacArthur saw the new centre – a joint initiative of the Garvan Institute in Sydney and the Murdoch Children’s Institute in Melbourne – as the chance to bring his years of expertise in genomic medicine back to Australia.

“The centre’s focus is applying a lot of the lessons we had learned in the early days in building the field of genomic medicine, particularly in places like the US and the UK, and applying it in the context of the Australian community,” MacArthur says.

MacArthur will outline his ­vision for genomic medicine in Australia at the Sohn Hearts & Mind Conference in Sydney on Friday.

The conference, which features top fund managers from Australia and around the world giving their best stock tips, has raised $60m for medical research in Australia since it began in 2016.

This is the first year that The Centre for Population Genomics, which has been funded from a combination of government grants and philanthropy, will receive funding from the conference.

MacArthur says his aim at the conference will be to explain the potential of the developing field of genomic medicine in Australia, adding that it is “an exciting time for the field”.

While genetics involves the study of how a person’s genes can cause a disease or an illness, the newer field of genomics involves the study of all of a person’s genes – the genome – looking at how the combination of genetic factors and environment can cause disease.

“All conditions, including the big killers like heart disease and cancer, have a contribution from both our DNA and the environment,” MacArthur says.

“If we can better understand the DNA component, it makes it a lot easier for us to identify the ­people who are most at risk of those conditions and give them the information they might need to make lifestyle changes, and also to think about how we might be able to develop therapies which could reduce the risk of those ­conditions.”

MacArthur’s work has included understanding the basis of certain rare genetic disorders, which can cause diseases such as muscular dystrophy and which particularly affect children.

Working in Boston, he oversaw a program that sequenced and analysed genomic data from more than 10,000 people from families with rare diseases – work that contributed to the discovery of more than 100 new rare disease genes.

‘We can now think about making precise changes to someone’s DNA’

Daniel MacArthur, genomic scientist

But Australia’s racial mix – which includes many people from Asia, the Middle East and South Pacific – is very different to that in the European nations that have provided the basis for a lot of genomic medicine research to date.

“My driving purpose with the centre is thinking about ways we can make sure the benefit of new technologies is available to all Australians, regardless of their background,” MacArthur said.

“We are focused on working directly with communities to build up a better picture of the patterns of genetic variation that exist within the Australian community and use it to predict and build better tools for the diagnosis, prediction and treatment of ­disease.”

When MacArthur left Australia, in 2007, after completing his PhD in human genetics at the University of Sydney, there was little work being done in the field of genomics. “But since then, there has been a huge amount of work to build up the infrastructure and the approaches to it,” he says.

“The centre, is a partnership between two different institutions in Sydney and Melbourne, is a new approach to bringing together genetic information at a very large scale in a way which can benefit Australian communities, not just the ones that are already being studied in other places around the world.”

MacArthur is based in Sydney and oversees a team that has members in Sydney, Melbourne and New Zealand.

One of his goals is to build a ­genomic data base from about 10,000 people from specific groups in Australia, including people from the Pacific, Southeast Asia, the Middle East and East ­Africa, to help study diseases in those populations.

“More than a quarter of Australian citizens were born overseas and more than half have at least one parent born overseas,” he says. “It is essential we have a genetic resource which is fit for purpose in our own country, which captures the full spectrum of diversity which exists here.”

He says the study of genomic medicine is now taking off as a result of a combination of factors including a sharp drop in the cost of the technology involved.

“The first human genome, which took about 10 years to ­sequence by a team of scientists around the world, was released in 2003, and took about $3bn to generate,” he says. “These days we can sequence a genome for less than $1000. It takes a week and is more accurate than the genome we generated back in 2003.

“It is an almost unprecedented drop in the cost of the technology which allows us to think about ­applying genomics to so many people around the world and so many patients.”

Big advances in data science such as cloud computing and the broader availability of artificial intelligence have also allowed for much easier processing of huge amounts of data.

“These technologies are now the key factor in our ability to make sense of the data and use it to diagnose, predict and treat disease,” MacArthur says.

There have also been big advances in the drugs and therapeutics available to treat diseases.

“It means we can now think about making precise changes to someone’s DNA in ways which can help cure their condition, or even potentially prevent a condition that they might go on to develop in future,” MacArthur says.

The Australian is a media partner of Sohn Hearts & Minds. You can watch Prof Daniel MacArthur's presentation from the event here.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Based in Boston as co-director of the Medical and Population Genomics Program at the Broad Institute for Mendelian Genomics at MIT and Harvard, his work in the US had involved using new genomic technologies to help predict and diagnose diseases.

It included overseeing a team that built one of the largest genetic data bases ever assembled, collecting data from more than 140,000 people.

MacArthur saw the new centre – a joint initiative of the Garvan Institute in Sydney and the Murdoch Children’s Institute in Melbourne – as the chance to bring his years of expertise in genomic medicine back to Australia.

“The centre’s focus is applying a lot of the lessons we had learned in the early days in building the field of genomic medicine, particularly in places like the US and the UK, and applying it in the context of the Australian community,” MacArthur says.

MacArthur will outline his ­vision for genomic medicine in Australia at the Sohn Hearts & Mind Conference in Sydney on Friday.

The conference, which features top fund managers from Australia and around the world giving their best stock tips, has raised $60m for medical research in Australia since it began in 2016.

This is the first year that The Centre for Population Genomics, which has been funded from a combination of government grants and philanthropy, will receive funding from the conference.

MacArthur says his aim at the conference will be to explain the potential of the developing field of genomic medicine in Australia, adding that it is “an exciting time for the field”.

While genetics involves the study of how a person’s genes can cause a disease or an illness, the newer field of genomics involves the study of all of a person’s genes – the genome – looking at how the combination of genetic factors and environment can cause disease.

“All conditions, including the big killers like heart disease and cancer, have a contribution from both our DNA and the environment,” MacArthur says.

“If we can better understand the DNA component, it makes it a lot easier for us to identify the ­people who are most at risk of those conditions and give them the information they might need to make lifestyle changes, and also to think about how we might be able to develop therapies which could reduce the risk of those ­conditions.”

MacArthur’s work has included understanding the basis of certain rare genetic disorders, which can cause diseases such as muscular dystrophy and which particularly affect children.

Working in Boston, he oversaw a program that sequenced and analysed genomic data from more than 10,000 people from families with rare diseases – work that contributed to the discovery of more than 100 new rare disease genes.

‘We can now think about making precise changes to someone’s DNA’

Daniel MacArthur, genomic scientist

But Australia’s racial mix – which includes many people from Asia, the Middle East and South Pacific – is very different to that in the European nations that have provided the basis for a lot of genomic medicine research to date.

“My driving purpose with the centre is thinking about ways we can make sure the benefit of new technologies is available to all Australians, regardless of their background,” MacArthur said.

“We are focused on working directly with communities to build up a better picture of the patterns of genetic variation that exist within the Australian community and use it to predict and build better tools for the diagnosis, prediction and treatment of ­disease.”

When MacArthur left Australia, in 2007, after completing his PhD in human genetics at the University of Sydney, there was little work being done in the field of genomics. “But since then, there has been a huge amount of work to build up the infrastructure and the approaches to it,” he says.

“The centre, is a partnership between two different institutions in Sydney and Melbourne, is a new approach to bringing together genetic information at a very large scale in a way which can benefit Australian communities, not just the ones that are already being studied in other places around the world.”

MacArthur is based in Sydney and oversees a team that has members in Sydney, Melbourne and New Zealand.

One of his goals is to build a ­genomic data base from about 10,000 people from specific groups in Australia, including people from the Pacific, Southeast Asia, the Middle East and East ­Africa, to help study diseases in those populations.

“More than a quarter of Australian citizens were born overseas and more than half have at least one parent born overseas,” he says. “It is essential we have a genetic resource which is fit for purpose in our own country, which captures the full spectrum of diversity which exists here.”

He says the study of genomic medicine is now taking off as a result of a combination of factors including a sharp drop in the cost of the technology involved.

“The first human genome, which took about 10 years to ­sequence by a team of scientists around the world, was released in 2003, and took about $3bn to generate,” he says. “These days we can sequence a genome for less than $1000. It takes a week and is more accurate than the genome we generated back in 2003.

“It is an almost unprecedented drop in the cost of the technology which allows us to think about ­applying genomics to so many people around the world and so many patients.”

Big advances in data science such as cloud computing and the broader availability of artificial intelligence have also allowed for much easier processing of huge amounts of data.

“These technologies are now the key factor in our ability to make sense of the data and use it to diagnose, predict and treat disease,” MacArthur says.

There have also been big advances in the drugs and therapeutics available to treat diseases.

“It means we can now think about making precise changes to someone’s DNA in ways which can help cure their condition, or even potentially prevent a condition that they might go on to develop in future,” MacArthur says.

The Australian is a media partner of Sohn Hearts & Minds. You can watch Prof Daniel MacArthur's presentation from the event here.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on Nov 15, 2023. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Ravi Chopra's Azora Capital had its best month in March when it shorted the US banks that failed. Picture: Jaclyn LichtRavi Chopra's Azora Capital had its best month in March when it shorted the US banks that failed. Picture: Jaclyn LichtRavi Chopra's Azora Capital had its best month in March when it shorted the US banks that failed. Picture: Jaclyn LichtRavi Chopra's Azora Capital had its best month in March when it shorted the US banks that failed. Picture: Jaclyn Licht
October 23, 2023

US Bank Run Has Slowed To A Walk, But Instability Remains

When Ravi Chopra reveals his stock pick at the prestigious Sohn Hearts & Minds conference at the Opera House in Sydney next month, it could well be a short bet on a US bank.

Read More
October 18, 2023

Two small caps: Propel Funeral Services (ASX: PFP) and Clarity Pharmaceuticals (ASX: CU6)

Get to know our 2023 Conference Fund Manager Rikki Bannan of IFM Investors who recently featured on the Equity Mates Media podcast.

Read More
October 16, 2023

How this hedge fund pulled off 2023’s ‘big short’

Last year, Ravi Chopra was travelling through Europe to shop his latest short idea to potential investors. “Financials are really all in the weeds,” he told The Australian Financial Review in an interview from New York.

Read More
IFM Investors executive director Rikki Bannan is a keen follower of stocks in the healthcare sector, but she knows it can be a risky place to invest.IFM Investors executive director Rikki Bannan is a keen follower of stocks in the healthcare sector, but she knows it can be a risky place to invest.IFM Investors executive director Rikki Bannan is a keen follower of stocks in the healthcare sector, but she knows it can be a risky place to invest.IFM Investors executive director Rikki Bannan is a keen follower of stocks in the healthcare sector, but she knows it can be a risky place to invest.
October 10, 2023

Beware the pitfalls of investing in healthcare, says IFM boss

“Healthcare is often viewed as a stable, defensive sector to invest in, but in small caps that hasn’t necessarily proven to be the case,” she says in an interview ahead of her appearance at the Sohn Hearts & Minds Conference 2023.

Read More
October 6, 2023

Secret to a long life cheaper than you think celebrity physician Peter Attia reveals

Don't miss Dr Peter Attia who will speak at the Sohn Hearts & Minds Conference at the Sydney Opera House next month.

Read More
Angela Aldrich of Bayberry Capital Partners in New York. Picture: Jaclyn Licht.Angela Aldrich of Bayberry Capital Partners in New York. Picture: Jaclyn Licht.Angela Aldrich of Bayberry Capital Partners in New York. Picture: Jaclyn Licht.Angela Aldrich of Bayberry Capital Partners in New York. Picture: Jaclyn Licht.
September 18, 2023

‘Volatility is opportunity’: why this manager loves shorting stocks

Angela Aldrich of Bayberry Capital Partners LP bet against Treasury Wine Estates at the top of the market and now she's preparing to make her next big call at this year's Sohn Hearts & Minds Conference.

Read More
September 15, 2023

Top fund managers share 11 stock picks for the long term

After a dramatic earnings season, fund managers, including Jessica Farr-Jones of Regal Funds and Kieran Moore of Munro Partners (HM1 Core Fund Managers), have shared some of their top picks for long-term growth.

Read More
September 11, 2023

Investors Sweeten On Hedge Funds As Rates Climb

After a decade of easy money pushing equity markets in one direction, Wall Street hedge fund manager Ricky Sandler says the return of volatility and higher interest rates is seeing money return to long-short strategies.

Read More
Eminence Capital CEO Ricky Sandler, left, with Sohn Australia co-founder Matthew Grounds. Picture: John FederEminence Capital CEO Ricky Sandler, left, with Sohn Australia co-founder Matthew Grounds. Picture: John FederEminence Capital CEO Ricky Sandler, left, with Sohn Australia co-founder Matthew Grounds. Picture: John FederEminence Capital CEO Ricky Sandler, left, with Sohn Australia co-founder Matthew Grounds. Picture: John Feder
September 11, 2023

Stock Stars Look Under The Surface

Influential New York-hedge fund manager Ricky Sandler returns to Australia to make a new pick at this year’s Sohn Hearts & Minds conference that will be held at the Sydney Opera House on November 17.

Read More
Barrenjoey co-executive chairman Matthew Grounds and New York-based Eminence Capital fund manager Ricky Sandler will be at the eighth Sohn Hearts & Minds conference. Picture: Peter RaeBarrenjoey co-executive chairman Matthew Grounds and New York-based Eminence Capital fund manager Ricky Sandler will be at the eighth Sohn Hearts & Minds conference. Picture: Peter RaeBarrenjoey co-executive chairman Matthew Grounds and New York-based Eminence Capital fund manager Ricky Sandler will be at the eighth Sohn Hearts & Minds conference. Picture: Peter RaeBarrenjoey co-executive chairman Matthew Grounds and New York-based Eminence Capital fund manager Ricky Sandler will be at the eighth Sohn Hearts & Minds conference. Picture: Peter Rae
September 11, 2023

Top Ny Stock Picker Warns Inflation To Remain Above Pre-Covid Levels

Influential New York hedge fund manager Ricky Sandler of Eminence Capital returns for the 2023 Sohn Hearts & Minds Conference in Sydney and says no one is focused on picking interesting, idiosyncratic stocks.

Read More
August 4, 2023

New Relic

New Relic was pitched by Ricky Sandler of Eminence Capital at the 2022 Sohn Hearts & Minds Conference.

Read More
June 18, 2023

Investors can’t agree how to value the world’s hottest stock

Despite mixed investor opinions, Munro Partners (Core Fund Manager) remains a strong believer in Nvidia. They are standing firm in their investment and still consider it a solid buy.

Read More
June 8, 2023

Stock pickers bet the field in slowing domestic market

Fund managers have batted away fears of an inflation-led recession, with Qantas, Seven Group and Treasury Wines named among the best investments by Australia’s top stock pickers.

Read More
March 27, 2023

The imaginary nepotism that drives Carsales global growth

The long-term approach of Carsales (2022 Conference stock pick) and its CEO Cameron McIntyre has delivered big gains for investors. He reveals his secret to staying strategic.

Read More
March 12, 2023

Jun Bei Liu is not giving up on the China reopening theme

Tribeca’s Jun Bei Liu says China’s reopening is only getting started, and names five ASX stocks set to benefit.

Read More